$BIAF News

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026

bioAffinity Technologies To Present New Data On Sputum-Based Tests In Development To Characterize Lung Inflammation And Detect Multiple Protein Biomarkers Of Lung Inflammation At CHEST 2026

WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies Receives Japanese Patent Allowance for CyPath Lung AI Diagnostic Test

bioAffinity Technologies Commences ~$4M Offering Of Common Stock At $6.122 Per Share

bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm

bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026

bioAffinity Technologies Announces 100% Increase In Sales For Its CyPath Lung Test For Lung Cancer

bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL

bioAffinity Technologies, AvMEDICAL Deliver First Joint Exhibition Of CyPath Lung

bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection

bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference

bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference

bioAffinity Technologies To Present Clinical And Veteran-Focused Data On CyPath Lung At NAVREF 2026 Annual Conference

BioAffinity Technologies Stock Surges Following Hong Kong Patent Grant

bioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer Diagnostic